- Participation as a Founding Partner of Future Health reinforces M42’s commitment to helping advance Abu Dhabi’s position as a global hub for health innovation and life sciences
- M42 leadership to contribute to conversations shaping the future of health across the three-day Summit
Abu Dhabi, UAE, 12 October 2026: M42, a global health leader powered by artificial intelligence (AI), technology and genomics, will participate at the Abu Dhabi Future Health Summit (ADFHS) 2026 as a Founding Partner of Future Health – A Global Initiative by Abu Dhabi. Taking place on 20–22 October at ADNEC Centre Abu Dhabi, M42 will bring together its leadership, clinical, genomic and environmental expertise and digital health technologies to demonstrate how connected health intelligence can help transform the future of care.
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council and hosted by the Department of Health – Abu Dhabi (DoH), the Summit is the flagship annual gathering of Future Health. The 2026 edition will take place under the theme “To Sense is to Predict,” reflecting a global shift towards more predictive and preventive approaches to health, grounded in early awareness, continuous sensing and data-led insights.
As a Founding Partner, M42 is helping advance a shared ambition to translate innovation, research and collaboration into measurable health impact. Its role reflects a long-term commitment that extends beyond the three-day Summit, contributing to a year-round global platform designed to connect ideas, expertise and action and accelerate solutions that enable longer, healthier lives.
Under the banner “One Ecosystem. One Intelligence. One Healthier Life”, M42 will showcase its full health intelligence infrastructure, encourage debate on advancing global health systems, cultivating the next generation of medicine, care and talent, and leveraging health intelligence for predictive, preventive and personalized care.
Dimitris Moulavasilis, Group Chief Executive Officer, M42, said: “The future of health will not be shaped by any single technology or breakthrough, but by connecting intelligence across the health ecosystem and translating it into earlier risk identification, preventive interventions and precision care. The Abu Dhabi Future Health Summit provides an important platform to demonstrate what that looks like in practice, exchange perspectives with leaders in the UAE and from around the world and enter partnerships to scale solutions that support patients, improve population health and build sustainable health systems.”
M42’s participation reflects its ambition to shift healthcare from a predominantly reactive model towards one that is increasingly predictive, preventive and personalized. By connecting capabilities across clinical care, genomics, biobanking, AI and digital health, M42 is working to translate advances in science and technology into solutions that can improve health at the individual, population and health systems levels.
Throughout the three-day Summit, M42 will showcase the full breadth of its capabilities, provide a platform for discussion and make announcements on M42’s growth, collaborations and innovations.
ADFHS 2026 is expected to bring together 16,000 attendees, 300 speakers and participants from 100 countries, building on the success of its 2025 edition, which welcomed more than 14,000 visitors and 271 speakers from 95 countries.
– ENDS –
About M42
M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally.
Established in 2023, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers, including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
About Future Health – A Global Initiative by Abu Dhabi
Future Health is a year-round platform for global collaboration and transformative health innovation, held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council.
Bringing together health researchers, policymakers, business leaders, investors and entrepreneurs from across disciplines and geographies, Future Health drives collective action to strengthen health systems and unlock longer, healthier lives for all.
Through a year-round programme of research insights, publications, impact initiatives, Challenges, R&D funding, and cross-sector convenings, Future Health advances progress across four focus areas: longevity and precision medicine, health systems and sustainability, digital health and AI, and investment in life sciences.
Future Health is curated and convened by the Department of Health – Abu Dhabi and its Founding Partners: PureHealth, M42, Institute for Healthier Living Abu Dhabi, and Mubadala Bio. Mediclinic Middle East serves as Strategic Partner and Burjeel Holdings as Associate Partner.
For more information, visit http://www.futurehealthinitiative.ae and follow Future Health on: X, Instagram, LinkedIn and Facebook.
For media inquiries, please contact media@futurehealthinitiative.ae
